North America Biosimilars Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Disease Indication (Cancer, Diabetes, Autoimmune Diseases, and Other Diseases), Drug Class (Granulocyte Colony-Stimulating Factors, Human Growth Hormone, Insulin, TNF Blockers & Monoclonal Antibodies, Erythropoietin-Stimulating Agents, and Others), Route of Administration (Intravenous, Subcutaneous, and Others), and End User (Hospitals, Speciality Clinics, Homecare, and Others)
The North America biosimilars market is expected to grow from US$ 7,115.74 million in 2022 to US$ 47,746.80 million by 2028. It is estimated to grow at a CAGR of 37.3% from 2022 to 2028.
Increasing Prevalence of Chronic Diseases is Driving North America Biosimilars Market
The increasing aging population, changing social behavior, and the rising adoption of a sedentary lifestyle by people with accelerating urbanization boost the prevalence of obesity and various chronic diseases, such as diabetes. Also, twin studies have long established that genes can cause chronic conditions such as cardiovascular disease (CVDs), diabetes, obesity, Alzheimer's disease (AD), and depression. According to the National Council on Aging, Inc., 80% of adults 65 and more have at least one chronic condition, while 68% have two or more. According to the Centers for Disease Control and Prevention (CDC), in 2020, almost 6 in 10 people in the US suffered from at least one chronic disease, and 4 in 10 people had two or more chronic conditions.
Cardiovascular diseases such as atherosclerosis, angina pectoris, and acute myocardial infarction, caused due to hectic lifestyles, are significant causes of mortality across the world. As per the data provided by the WHO, CVDs are the number one cause of death worldwide, recording estimated 17.9 million deaths each year. Diabetes is a life-threatening chronic disease with no functional cure. Diabetes of all types can lead to various complications in different body parts and increase the overall risk of premature death. Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are among the major complications associated with diabetes. According to the International Diabetes Federation (IDF), diabetic cases in North America are expected to reach 62 million by 2045 from 46 million in 2017. Furthermore, the data reported that 425 million people were suffering from diabetes in 2017, and the count is expected to reach 629 million by 2045 across the world. The disease prevalence is likely to increase by about 35% during the forecast period.
North America Biosimilars Market Overview
According to NIH Autoimmune Diseases Coordinating Committee, in 2019, more than 24 million Americans suffer from autoimmune diseases. Eight million people have auto-antibodies, blood molecules that indicate a person's risk of developing autoimmune diseases. For unknown reasons, autoimmune diseases are affecting more people. According to the Clinical Research Branch at the National Institute of Environmental Health Sciences (NIEHS), in 2020, there is a significant increase in the prevalence of antinuclear antibodies (ANA), the most common biomarker of autoimmunity in the US. The study is the first to evaluate ANA changes in a representative sampling of the US population over time. It includes males, non-Hispanic whites, adults over 50, and adolescents. In the US, biosimilars are used to treat patients with cancers, kidney diseases, diabetes, and other autoimmune diseases such as rheumatoid arthritis and Crohn's disease. According to Cardinal Health, a total of 33 biosimilars have been approved by the FDA in the US and 21 are commercially available. Of the 21 biosimilars on the market, 17 are used for treatments associated with cancers, three are used to treat autoimmune conditions and one is used to treat diabetes.
North America Biosimilars Market Revenue and Forecast to 2028 (US$ Million)
North America Biosimilars Market Segmentation
The North America biosimilars market is segmented into disease indication, drug class, route of administration, end user, and country.
Based on disease indication, the biosimilars market is segmented into cancer, diabetes, autoimmune diseases, and other disease indications. The cancer segment held the largest market share in 2022.
The biosimilars market, based on drug class, is segmented into granulocyte colony-stimulating stimulating factors, human growth hormone, insulin, TNF blockers & monoclonal antibodies, erythropoietin-stimulating stimulating agents, and others. The granulocyte colony-stimulating factors segment accounted for the largest share of the market in 2022.
Based on route of administration, the biosimilar market is segmented into intravenous, subcutaneous, and others. The intravenous segment accounted for the largest share of the market in 2022.
The biosimilars market, based on end user, is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment accounted for the largest share of the market in 2022.
Based on country, the North America biosimilars market is segmented into the US, Canada, and Mexico. The US dominated the market in 2022.
Amgen Inc; Celltrion Inc; Sanofi SA; Biocon Ltd; Coherus BioSciences Inc; Eli Lilly and Co; Sandoz AG; Teva Pharmaceutical Industries Ltd; Pfizer Inc; and Dr. Reddy's Laboratories Ltd are the leading companies operating in the North America biosimilars market.
Increasing Prevalence of Chronic Diseases is Driving North America Biosimilars Market
The increasing aging population, changing social behavior, and the rising adoption of a sedentary lifestyle by people with accelerating urbanization boost the prevalence of obesity and various chronic diseases, such as diabetes. Also, twin studies have long established that genes can cause chronic conditions such as cardiovascular disease (CVDs), diabetes, obesity, Alzheimer's disease (AD), and depression. According to the National Council on Aging, Inc., 80% of adults 65 and more have at least one chronic condition, while 68% have two or more. According to the Centers for Disease Control and Prevention (CDC), in 2020, almost 6 in 10 people in the US suffered from at least one chronic disease, and 4 in 10 people had two or more chronic conditions.
Cardiovascular diseases such as atherosclerosis, angina pectoris, and acute myocardial infarction, caused due to hectic lifestyles, are significant causes of mortality across the world. As per the data provided by the WHO, CVDs are the number one cause of death worldwide, recording estimated 17.9 million deaths each year. Diabetes is a life-threatening chronic disease with no functional cure. Diabetes of all types can lead to various complications in different body parts and increase the overall risk of premature death. Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are among the major complications associated with diabetes. According to the International Diabetes Federation (IDF), diabetic cases in North America are expected to reach 62 million by 2045 from 46 million in 2017. Furthermore, the data reported that 425 million people were suffering from diabetes in 2017, and the count is expected to reach 629 million by 2045 across the world. The disease prevalence is likely to increase by about 35% during the forecast period.
North America Biosimilars Market Overview
According to NIH Autoimmune Diseases Coordinating Committee, in 2019, more than 24 million Americans suffer from autoimmune diseases. Eight million people have auto-antibodies, blood molecules that indicate a person's risk of developing autoimmune diseases. For unknown reasons, autoimmune diseases are affecting more people. According to the Clinical Research Branch at the National Institute of Environmental Health Sciences (NIEHS), in 2020, there is a significant increase in the prevalence of antinuclear antibodies (ANA), the most common biomarker of autoimmunity in the US. The study is the first to evaluate ANA changes in a representative sampling of the US population over time. It includes males, non-Hispanic whites, adults over 50, and adolescents. In the US, biosimilars are used to treat patients with cancers, kidney diseases, diabetes, and other autoimmune diseases such as rheumatoid arthritis and Crohn's disease. According to Cardinal Health, a total of 33 biosimilars have been approved by the FDA in the US and 21 are commercially available. Of the 21 biosimilars on the market, 17 are used for treatments associated with cancers, three are used to treat autoimmune conditions and one is used to treat diabetes.
North America Biosimilars Market Revenue and Forecast to 2028 (US$ Million)
North America Biosimilars Market Segmentation
The North America biosimilars market is segmented into disease indication, drug class, route of administration, end user, and country.
Based on disease indication, the biosimilars market is segmented into cancer, diabetes, autoimmune diseases, and other disease indications. The cancer segment held the largest market share in 2022.
The biosimilars market, based on drug class, is segmented into granulocyte colony-stimulating stimulating factors, human growth hormone, insulin, TNF blockers & monoclonal antibodies, erythropoietin-stimulating stimulating agents, and others. The granulocyte colony-stimulating factors segment accounted for the largest share of the market in 2022.
Based on route of administration, the biosimilar market is segmented into intravenous, subcutaneous, and others. The intravenous segment accounted for the largest share of the market in 2022.
The biosimilars market, based on end user, is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment accounted for the largest share of the market in 2022.
Based on country, the North America biosimilars market is segmented into the US, Canada, and Mexico. The US dominated the market in 2022.
Amgen Inc; Celltrion Inc; Sanofi SA; Biocon Ltd; Coherus BioSciences Inc; Eli Lilly and Co; Sandoz AG; Teva Pharmaceutical Industries Ltd; Pfizer Inc; and Dr. Reddy's Laboratories Ltd are the leading companies operating in the North America biosimilars market.
1. INTRODUCTION
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Biosimilars Market – by Disease Indication
1.3.2 North America Biosimilars Market – by Drug class
1.3.3 North America Biosimilars Market – by Route of Administration
1.3.4 North America Biosimilars Market – by End User
1.3.5 North America Biosimilars Market – by Country
2. NORTH AMERICA BIOSIMILARS MARKET – KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. NORTH AMERICA BIOSIMILARS MARKET – MARKET LANDSCAPE
4.1 Overview
4.2 North America PEST Analysis
4.3 Expert’s Opinion
5. NORTH AMERICA BIOSIMILARS MARKET – KEY MARKET DYNAMICS
5.1 Market Drivers
5.1.1 Increasing Prevalence of Chronic Diseases
5.1.2 Cost Effectiveness of Biosimilar Drugs
5.1.3 Rising Approvals of Biosimilars
5.2 Market Restraints
5.2.1 High-Cost Involvement and Complexities in Biosimilar Product Manufacturing
5.3 Market Opportunities
5.3.1 Patent Expiry of Blockbuster Biologics
5.4 Future Trend
5.4.1 Collaborations for Biosimilars and Clinical Trials
5.5 Impact analysis
6. BIOSIMILARS MARKET – NORTH AMERICA ANALYSIS
6.1 North America Biosimilars Market Revenue Forecast and Analysis
7. NORTH AMERICA BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2028 – BY DISEASE INDICATION
7.1 Overview
7.2 North America Biosimilars Market Revenue Share, by disease indication 2021 & 2028 (%)
7.3 Cancer
7.3.1 Overview
7.3.2 Cancer: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Diabetes
7.4.1 Overview
7.4.2 Diabetes: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Autoimmune Diseases
7.5.1 Overview
7.5.2 Autoimmune Diseases: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5.3 Psoriasis:
7.5.3.1 Overview
7.5.3.2 Psoriasis: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5.4 Arthritis:
7.5.4.1 Overview
7.5.4.2 Arthritis: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5.5 Others:
7.5.5.1 Overview
7.5.5.2 Others: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Others Disease Indications
7.6.1 Overview
7.6.2 Others Disease Indications: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8. NORTH AMERICA BIOSIMILARS MARKET ANALYSIS AND FORECAST TO 2028 – BY DRUG CLASS
8.1 Overview
8.2 North America Biosimilars Market, by Drug class 2021 & 2028 (%)
8.3 Granulocyte colony-stimulating factors
8.3.1 Overview
8.3.2 Granulocyte colony-stimulating factors Drug class: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Insulin
8.4.1 Overview
8.4.2 Insulin Drug class: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.5 TNF Blockers and Monoclonal Antibodies
8.5.1 Overview
8.5.2 TNF Blockers and Monoclonal Antibodies Drug class: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others Drug class: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
9. NORTH AMERICA BIOSIMILARS MARKET ANALYSIS AND FORECASTS TO 2028 – BY ROUTE OF ADMINISTRATION
9.1 Overview
9.2 North America Biosimilars Market, by Application 2021 & 2028 (%)
9.3 Intravenous
9.3.1 Overview
9.3.2 Intravenous: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Subcutaneous
9.4.1 Overview
9.4.2 Subcutaneous: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10. NORTH AMERICA BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2028 – BY END USER
10.1 Overview
10.2 North America Biosimilars Market Revenue Share, by End User 2021 & 2028 (%)
10.3 Hospitals
10.3.1 Overview
10.3.2 Hospitals: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10.4 Specialty Clinics
10.4.1 Overview
10.4.2 Specialty Clinics: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10.5 Homecare
10.5.1 Overview
10.5.2 Homecare: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10.6 Other
10.6.1 Overview
10.6.2 Other: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11. NORTH AMERICA BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2028 – COUNTRY ANALYSIS
11.1 Overview
11.1.1.1 US: Biosimilar Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.1.1 Overview
11.1.1.1.2 US: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million)
11.1.1.1.3 US: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.1.3.1 US: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.1.4 US: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.1.5 US: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.1.6 US: Biosimilar Market, by End User, 2019–2028 (US$ Million)
11.1.1.2 Canada: Biosimilar Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.2.1 Canada: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million)
11.1.1.2.2 Canada: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.2.2.1 Canada: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.2.3 Canada: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.2.4 Canada: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.2.5 Canada: Biosimilar Market, by End User, 2019–2028 (US$ Million)
11.1.1.3 Mexico: Biosimilar Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.3.1 Mexico: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million)
11.1.1.3.2 Mexico: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.3.2.1 Mexico: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.3.3 Mexico: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.3.4 Mexico: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.3.5 Mexico: Biosimilar Market, by End User, 2019–2028 (US$ Million)
12. BIOSIMILARS MARKET – INDUSTRY LANDSCAPE
12.1 Overview
12.2 Growth Strategies in the Biosimilars Market
12.3 Inorganic Growth Strategies
12.3.1 Overview
12.4 Organic Growth Strategies
12.4.1 Overview
13. COMPANY PROFILES
13.1 Amgen Inc
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Celltrion Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Sanofi SA
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Biocon Ltd
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Coherus BioSciences Inc
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Eli Lilly and Co
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Sandoz AG
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Teva Pharmaceutical Industries Ltd
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Pfizer Inc
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Dr. Reddy's Laboratories Ltd
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. APPENDIX
14.1 About The Insight Partners
14.2 Glossary of Terms
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Biosimilars Market – by Disease Indication
1.3.2 North America Biosimilars Market – by Drug class
1.3.3 North America Biosimilars Market – by Route of Administration
1.3.4 North America Biosimilars Market – by End User
1.3.5 North America Biosimilars Market – by Country
2. NORTH AMERICA BIOSIMILARS MARKET – KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. NORTH AMERICA BIOSIMILARS MARKET – MARKET LANDSCAPE
4.1 Overview
4.2 North America PEST Analysis
4.3 Expert’s Opinion
5. NORTH AMERICA BIOSIMILARS MARKET – KEY MARKET DYNAMICS
5.1 Market Drivers
5.1.1 Increasing Prevalence of Chronic Diseases
5.1.2 Cost Effectiveness of Biosimilar Drugs
5.1.3 Rising Approvals of Biosimilars
5.2 Market Restraints
5.2.1 High-Cost Involvement and Complexities in Biosimilar Product Manufacturing
5.3 Market Opportunities
5.3.1 Patent Expiry of Blockbuster Biologics
5.4 Future Trend
5.4.1 Collaborations for Biosimilars and Clinical Trials
5.5 Impact analysis
6. BIOSIMILARS MARKET – NORTH AMERICA ANALYSIS
6.1 North America Biosimilars Market Revenue Forecast and Analysis
7. NORTH AMERICA BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2028 – BY DISEASE INDICATION
7.1 Overview
7.2 North America Biosimilars Market Revenue Share, by disease indication 2021 & 2028 (%)
7.3 Cancer
7.3.1 Overview
7.3.2 Cancer: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Diabetes
7.4.1 Overview
7.4.2 Diabetes: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Autoimmune Diseases
7.5.1 Overview
7.5.2 Autoimmune Diseases: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5.3 Psoriasis:
7.5.3.1 Overview
7.5.3.2 Psoriasis: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5.4 Arthritis:
7.5.4.1 Overview
7.5.4.2 Arthritis: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5.5 Others:
7.5.5.1 Overview
7.5.5.2 Others: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Others Disease Indications
7.6.1 Overview
7.6.2 Others Disease Indications: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8. NORTH AMERICA BIOSIMILARS MARKET ANALYSIS AND FORECAST TO 2028 – BY DRUG CLASS
8.1 Overview
8.2 North America Biosimilars Market, by Drug class 2021 & 2028 (%)
8.3 Granulocyte colony-stimulating factors
8.3.1 Overview
8.3.2 Granulocyte colony-stimulating factors Drug class: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Insulin
8.4.1 Overview
8.4.2 Insulin Drug class: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.5 TNF Blockers and Monoclonal Antibodies
8.5.1 Overview
8.5.2 TNF Blockers and Monoclonal Antibodies Drug class: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others Drug class: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
9. NORTH AMERICA BIOSIMILARS MARKET ANALYSIS AND FORECASTS TO 2028 – BY ROUTE OF ADMINISTRATION
9.1 Overview
9.2 North America Biosimilars Market, by Application 2021 & 2028 (%)
9.3 Intravenous
9.3.1 Overview
9.3.2 Intravenous: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Subcutaneous
9.4.1 Overview
9.4.2 Subcutaneous: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10. NORTH AMERICA BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2028 – BY END USER
10.1 Overview
10.2 North America Biosimilars Market Revenue Share, by End User 2021 & 2028 (%)
10.3 Hospitals
10.3.1 Overview
10.3.2 Hospitals: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10.4 Specialty Clinics
10.4.1 Overview
10.4.2 Specialty Clinics: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10.5 Homecare
10.5.1 Overview
10.5.2 Homecare: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10.6 Other
10.6.1 Overview
10.6.2 Other: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11. NORTH AMERICA BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2028 – COUNTRY ANALYSIS
11.1 Overview
11.1.1.1 US: Biosimilar Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.1.1 Overview
11.1.1.1.2 US: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million)
11.1.1.1.3 US: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.1.3.1 US: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.1.4 US: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.1.5 US: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.1.6 US: Biosimilar Market, by End User, 2019–2028 (US$ Million)
11.1.1.2 Canada: Biosimilar Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.2.1 Canada: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million)
11.1.1.2.2 Canada: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.2.2.1 Canada: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.2.3 Canada: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.2.4 Canada: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.2.5 Canada: Biosimilar Market, by End User, 2019–2028 (US$ Million)
11.1.1.3 Mexico: Biosimilar Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.3.1 Mexico: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million)
11.1.1.3.2 Mexico: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.3.2.1 Mexico: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.3.3 Mexico: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.3.4 Mexico: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.3.5 Mexico: Biosimilar Market, by End User, 2019–2028 (US$ Million)
12. BIOSIMILARS MARKET – INDUSTRY LANDSCAPE
12.1 Overview
12.2 Growth Strategies in the Biosimilars Market
12.3 Inorganic Growth Strategies
12.3.1 Overview
12.4 Organic Growth Strategies
12.4.1 Overview
13. COMPANY PROFILES
13.1 Amgen Inc
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Celltrion Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Sanofi SA
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Biocon Ltd
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Coherus BioSciences Inc
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Eli Lilly and Co
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Sandoz AG
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Teva Pharmaceutical Industries Ltd
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Pfizer Inc
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Dr. Reddy's Laboratories Ltd
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. APPENDIX
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Comparison Between Different Drug Developments
Table 2. US Biosimilar Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 3. US Biosimilar Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 4. US Biosimilar Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 5. US Biosimilar Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 6. US Biosimilar Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 7. Canada Biosimilar Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 8. Canada Biosimilar Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 9. Canada Biosimilar Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 10. Canada Biosimilar Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 11. Canada Biosimilar Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 12. Mexico Biosimilar Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 13. Mexico Biosimilar Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 14. Mexico Biosimilar Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 15. Mexico Biosimilar Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 16. Mexico Biosimilar Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 17. Recent Inorganic Growth Strategies in the Biosimilars Market
Table 18. Recent Organic Growth Strategies in the Biosimilars Market
Table 19. Glossary of Terms
Table 1. Comparison Between Different Drug Developments
Table 2. US Biosimilar Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 3. US Biosimilar Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 4. US Biosimilar Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 5. US Biosimilar Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 6. US Biosimilar Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 7. Canada Biosimilar Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 8. Canada Biosimilar Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 9. Canada Biosimilar Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 10. Canada Biosimilar Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 11. Canada Biosimilar Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 12. Mexico Biosimilar Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 13. Mexico Biosimilar Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 14. Mexico Biosimilar Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 15. Mexico Biosimilar Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 16. Mexico Biosimilar Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 17. Recent Inorganic Growth Strategies in the Biosimilars Market
Table 18. Recent Organic Growth Strategies in the Biosimilars Market
Table 19. Glossary of Terms
LIST OF FIGURES
Figure 1. North America Biosimilars Market Segmentation
Figure 2. North America Biosimilars Market, by Country
Figure 3. North America Biosimilars Market Overview
Figure 4. Cancer Segment Held Largest Share of Type Segment in North America Biosimilars Market
Figure 5. US is Expected to Show Remarkable Growth During Forecast Period
Figure 6. North America: PEST Analysis
Figure 7. Experts’ Opinion
Figure 8. North America Biosimilars Market Impact Analysis of Drivers and Restraints
Figure 9. North America Biosimilars Market – Revenue Forecast and Analysis – 2020–2028
Figure 10. North America Biosimilars Market Revenue Share, by disease indication 2021 & 2028 (%)
Figure 11. Cancer: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Diabetes: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Autoimmune Diseases: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Psoriasis: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Arthritis: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Others: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Others Disease Indications: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. North America Biosimilars Market, by Drug class 2021 & 2028 (%)
Figure 19. Granulocyte colony-stimulating factors Drug class: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Insulin Drug class: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. TNF Blockers and Monoclonal Antibodies Drug class: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Others Drug class: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. North America Biosimilars Market, by Application 2021 & 2028 (%)
Figure 24. Intravenous: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Subcutaneous: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Others: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. North America Biosimilars Market Revenue Share, by End User 2021 & 2028 (%)
Figure 28. Hospitals: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Specialty Clinics: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. Homecare: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. Other: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. North America: Biosimilar Market, by Key Country – Revenue (2022) (US$ Million)
Figure 33. North America: Biosimilar Market, by Country, 2021 & 2028 (%)
Figure 34. US Biosimilar Market Revenue and Forecast to 2028 (USD Million)
Figure 35. Canada Biosimilar Market Revenue and Forecast to 2028 (USD Million)
Figure 36. Mexico Biosimilar Market Revenue and Forecast to 2028 (USD Million)
Figure 37. Growth Strategies in the Biosimilars Market
Figure 1. North America Biosimilars Market Segmentation
Figure 2. North America Biosimilars Market, by Country
Figure 3. North America Biosimilars Market Overview
Figure 4. Cancer Segment Held Largest Share of Type Segment in North America Biosimilars Market
Figure 5. US is Expected to Show Remarkable Growth During Forecast Period
Figure 6. North America: PEST Analysis
Figure 7. Experts’ Opinion
Figure 8. North America Biosimilars Market Impact Analysis of Drivers and Restraints
Figure 9. North America Biosimilars Market – Revenue Forecast and Analysis – 2020–2028
Figure 10. North America Biosimilars Market Revenue Share, by disease indication 2021 & 2028 (%)
Figure 11. Cancer: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Diabetes: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Autoimmune Diseases: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Psoriasis: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Arthritis: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Others: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Others Disease Indications: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. North America Biosimilars Market, by Drug class 2021 & 2028 (%)
Figure 19. Granulocyte colony-stimulating factors Drug class: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Insulin Drug class: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. TNF Blockers and Monoclonal Antibodies Drug class: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Others Drug class: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. North America Biosimilars Market, by Application 2021 & 2028 (%)
Figure 24. Intravenous: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Subcutaneous: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Others: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. North America Biosimilars Market Revenue Share, by End User 2021 & 2028 (%)
Figure 28. Hospitals: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Specialty Clinics: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. Homecare: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. Other: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. North America: Biosimilar Market, by Key Country – Revenue (2022) (US$ Million)
Figure 33. North America: Biosimilar Market, by Country, 2021 & 2028 (%)
Figure 34. US Biosimilar Market Revenue and Forecast to 2028 (USD Million)
Figure 35. Canada Biosimilar Market Revenue and Forecast to 2028 (USD Million)
Figure 36. Mexico Biosimilar Market Revenue and Forecast to 2028 (USD Million)
Figure 37. Growth Strategies in the Biosimilars Market
